Genes2Me blog

Vector-borne diseases remain a major global health challenge, with infections like dengue, malaria, chikungunya, and Zika often sharing similar clinical symptoms. This overlap can delay accurate diagnosis and treatment.

Our latest blog explores how molecular diagnostic technologies, including Real-Time PCR and Multiplex PCR, enable rapid, highly sensitive, and specific detection of multiple pathogens, helping healthcare professionals make informed clinical decisions.

Read the full article: 🔗 https://genes2me.com/blog/2026/07/16/blog-molecular-diagnosis-vector-borne-diseases/

Genes2Me NIPT delivers accurate, non-invasive prenatal screening for common chromosomal abnormalities as early as the first trimester. Powered by advanced genomic science, it helps healthcare professionals make informed clinical decisions while giving expecting families greater confidence and reassurance.

Discover how Genes2Me NIPT supports reliable prenatal care with precision and trust.

📞 Contact us to learn more or visit our website for product details.

Cancer remains one of the leading global health challenges, requiring advanced diagnostic approaches that go beyond conventional methods. Next-Generation Sequencing (NGS) has revolutionized cancer diagnostics by enabling comprehensive genomic profiling and helping clinicians identify actionable mutations for personalized treatment decisions.

Genes2Me’s OncoCheck™, a comprehensive 53-gene NGS assay, is designed to support precision oncology by providing accurate detection of clinically relevant genetic alterations. Built using advanced hybrid-capture technology, OncoCheck™ offers reliable identification of Single Nucleotide Variants (SNVs), Insertions and Deletions (InDels), and Copy Number Variations (CNVs) from a single workflow.

This targeted oncology solution supports a variety of clinically relevant sample types, including FFPE tissue, fresh tissue samples, and blood-derived DNA, making it suitable for diverse cancer testing workflows. Combined with Cliseq® Interpreter, Genes2Me’s advanced bioinformatics platform, the assay transforms complex sequencing data into clear, actionable genomic insights.

As the field of precision oncology continues to evolve, comprehensive genomic testing has become essential for understanding tumor biology, identifying potential therapeutic targets, and supporting personalized patient management. By reducing the need for multiple single-gene tests, OncoCheck™ helps laboratories improve efficiency while conserving valuable patient samples.

Explore our NGS solutions to learn how advanced sequencing technologies are shaping the future of molecular diagnostics. Discover our oncology testing portfolio for comprehensive cancer genomic profiling, and learn more about Cliseq® Interpreter for streamlined bioinformatics analysis and clinical reporting.

With its clinically relevant 53-gene panel, robust hybrid-capture chemistry, broad sample compatibility, and integrated analysis support, OncoCheck™ empowers laboratories and healthcare professionals with high-confidence genomic insights that advance precision medicine and improve cancer care.